Pfizer was the first to launch a 5-in-1 meningococcal vaccine, Penbraya, two years ago but failed to capitalize on its advantage, and now rival GSK looks set to confirm its dominance in the field with its new product, Penmenvy.
GSK To Maintain Lead With Newly Approved Meningococcal Vaccine Penmenvy
Pfizer has been unable to take a big slice of the meningococcal vaccine market with Penbraya and now GSK looks set to consolidate its lead with its new 5-in-1 vaccine.
More from New Products
More from Therapy Areas
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.